Prochlorperazine-Induced Neuroleptic Malignant Syndrome

Neuroleptic malignant syndrome (NMS) is an uncommon but potentially fatal drug-induced neurological emergency. Its core clinical pattern includes hyperthermia, altered mental status, autonomic instability, and generalized skeletal-muscle rigidity. Because these features can overlap with serotonin syndrome, central nervous system infection, malignant hyperthermia, malignant catatonia, and seizure-related disorders, diagnosis depends on integrating medication exposure with the clinical course rather than interpreting one laboratory value in isolation.

The reference report, Prochlorperazine-induced neuroleptic malignant syndrome, is important because it documents NMS after exposure to a commonly used antiemetic. Prochlorperazine is a dopamine D2 receptor antagonist, and central dopamine-receptor blockade is a recognized mechanistic basis for NMS associated with antipsychotic and related drugs. The report therefore connects routine antiemetic therapy with a rare emergency presentation that may be missed when laboratory abnormalities are limited.

Study Background and Research Question

Prochlorperazine is primarily used to control nausea and vomiting, including symptoms associated with vestibular disorders. Its pharmacological activity extends beyond the gastrointestinal indication: dopamine-receptor antagonism can influence central thermoregulation, motor control, arousal, and autonomic function. In susceptible patients, this pharmacology may contribute to severe neurological toxicity even when the prescribed exposure is not described as excessive.

The report centers on a 76-year-old man with hypertension, type 2 diabetes, and chronic atrial fibrillation. Two weeks before emergency admission, he had begun taking prochlorperazine 5 mg twice daily for nausea related to peripheral vertigo. The research question was clinically practical: can prochlorperazine precipitate a syndrome meeting the clinical profile of NMS at a usual prescribed dosage, and how should clinicians approach diagnosis when expected biochemical abnormalities are absent or mild? The reference study addresses this question through a detailed case chronology rather than through a controlled experiment.

Key Innovation from the Reference Study

The main innovation is the report’s emphasis on a clinically convincing NMS phenotype with relatively limited laboratory support. On presentation, the patient had fever above 38 °C, tachycardia, rapid breathing, labile blood pressure, drowsiness, reduced motor activity, tremor, and generalized lead-pipe rigidity. His Glasgow Coma Scale score was 12, indicating moderate impairment. These findings formed a coherent syndrome even though the initial creatine phosphokinase level was only 256 U/L and later peaked at 454 U/L, values that might not immediately trigger recognition of severe muscle injury.

This discordance is meaningful for emergency medicine and pharmacovigilance. A normal white blood cell count, normal electrolytes, normal ammonia, and initially modest muscle-enzyme elevation could encourage premature dismissal of NMS. Instead, the authors show that a careful medication history and serial neurological assessment can identify a drug-induced syndrome before laboratory changes become pronounced. The case also broadens awareness of prochlorperazine as a possible precipitant, rather than limiting NMS consideration to conventional antipsychotic treatment.

Methods and Experimental Design Insights

Methodologically, this was a structured single-patient case report. The authors documented the recent drug exposure, baseline comorbidities, presenting symptoms, vital-sign abnormalities, neurological examination, laboratory tests, imaging, cerebrospinal-fluid analysis, electroencephalography, treatment, and follow-up. This design is appropriate for recognizing a rare adverse event, although it cannot estimate incidence or prove causality with the same strength as a prospective pharmacovigilance study.

The diagnostic process was deliberately exclusionary. An emergent brain CT was used to assess acute intracranial pathology. Lumbar puncture showed mildly elevated cerebrospinal-fluid protein but otherwise normal findings, reducing support for a central nervous system infection. EEG did not show epileptiform discharges. The absence of serotonin-related medication exposure, together with generalized rigidity and reduced reflexes, helped distinguish the presentation from serotonin syndrome. These steps illustrate a transferable approach: first identify the toxidromic pattern, then investigate competing neurological, infectious, and medication-related explanations.

Protocol Parameters

• Index exposure: The case involved prochlorperazine 5 mg twice daily for two weeks before admission; this is a report-specific exposure history, not a recommended treatment or challenge protocol, as detailed in the reference study.
• Clinical trigger for NMS evaluation: Fever above 38 °C, heart rate above 100 beats per minute, respiratory rate above 30 per minute, labile blood pressure, altered consciousness, tremor, and generalized lead-pipe rigidity were assessed together rather than as isolated findings.
• Laboratory context: The report recorded a white blood cell count of 4,140/μl, an initial creatine phosphokinase level of 256 U/L, and a later peak of 454 U/L. These values illustrate why serial testing and clinical reassessment are useful when NMS is suspected.
• Neurological exclusion testing: Brain CT, cerebrospinal-fluid examination, and EEG were used to evaluate structural, infectious, and seizure-related alternatives. Cerebrospinal-fluid protein was 66 mg/dL, with otherwise unremarkable analysis.
• Case-reported treatment: The patient received intravenous lorazepam 1 mg every 6 hours and oral amantadine 100 mg every 12 hours. These parameters describe the published management and should not replace institution-specific emergency protocols or specialist judgment.

Core Findings and Why They Matter

The patient’s presentation matched the major clinical domains of NMS: hyperthermia, mental-status change, autonomic dysregulation, and rigidity. Importantly, the report does not rely on a single diagnostic test. Normal electrolytes and ammonia made several metabolic explanations less likely, while the lack of acute findings on CT reduced concern for a structural brain event. Mild cerebrospinal-fluid protein elevation did not provide a persuasive alternative explanation, and the EEG findings did not support ongoing epileptic activity.

Management was followed by steady improvement. Fever resolved, consciousness returned to a full Glasgow Coma Scale score of 15, and generalized rigidity disappeared. Lorazepam was gradually tapered, while amantadine was continued at discharge and later discontinued after outpatient follow-up showed no recurrent altered mental status or rigidity. According to the reference report, the favorable outcome supports the practical value of early recognition, withdrawal of the suspected offending drug, close monitoring, and individualized pharmacotherapy.

The broader implication is not that every patient receiving prochlorperazine will develop NMS. Rather, the case establishes a safety signal that should inform clinical reasoning. In an older patient with new fever, rigidity, autonomic instability, and altered consciousness, recent exposure to a dopamine-blocking antiemetic deserves the same careful consideration given to other neuroleptic agents. A relatively low or slowly rising creatine phosphokinase level should not override a compelling clinical pattern.

Comparison with Existing Internal Articles

The internal article Prochlorperazine: Dopamine D₂ Antagonist and Antiemetic Insights presents prochlorperazine mainly through its receptor pharmacology, antiemetic therapy, and emerging laboratory applications. That perspective is complementary to the case report: the pharmacology explains why dopamine blockade is clinically useful for nausea, while the emergency-medicine paper demonstrates how the same broad pharmacological class can produce a rare, serious neurological adverse event.

A second internal resource, Prochlorperazine in Translational Research, discusses possible applications in melanoma research and other experimental systems. The reference case adds an essential safety boundary to that translational discussion. It concerns an acute human adverse event, not melanoma biology, antiviral activity, or cancer research efficacy, and therefore should not be used to infer therapeutic benefit in those areas.

Why this cross-domain matters, maturity, and limitations

Connecting antiemetic pharmacology with melanoma research or broader cancer research can help investigators recognize that a compound’s receptor profile may have both experimental opportunities and safety liabilities. However, the evidence streams have different maturity levels. The reference paper is a clinical case report focused on NMS, whereas laboratory observations in melanoma-related systems are preclinical and address different endpoints. They should be integrated only at the level of mechanism and safety awareness, not as evidence that treatment of one condition predicts efficacy in another.

Limitations and Transferability

The principal limitation is the single-patient design. One case cannot establish the frequency of prochlorperazine-associated NMS, identify a reliable dose-response relationship, or determine which comorbidities increase susceptibility. The patient’s age and chronic cardiovascular, metabolic, and atrial-fibrillation-related conditions may have influenced presentation or recovery, although the report states that no newly introduced medication other than prochlorperazine was identified during the preceding two weeks.

Causality also remains probabilistic. There was no intentional rechallenge, serum prochlorperazine concentration, comparator group, or formal prospective assessment of alternative causes. Improvement after treatment is clinically persuasive but does not isolate the contribution of lorazepam, amantadine, drug withdrawal, supportive care, or natural recovery. The absence of marked creatine phosphokinase elevation may reflect early presentation, individual variation, or the clinical spectrum of NMS, but the report cannot determine which explanation is correct.

Transferability is therefore strongest at the level of vigilance and diagnostic method. Researchers and clinicians can reasonably generalize the need to review dopamine-blocking medications, assess rigidity and autonomic instability, repeat relevant laboratory tests, and exclude competing emergencies. They should not generalize the reported treatment schedule as a universal regimen or use this case to calculate risk for younger patients, other indications, or different exposure durations.

Research Support Resources

For laboratory studies examining dopamine-receptor biology, membrane-trafficking questions, or melanoma-cell phenotypes, researchers can use Prochlorperazine (SKU A8508) to support similar in vitro workflows. Experimental use should be separated from clinical decision-making, with concentration selection, solvent controls, exposure duration, and cell-specific toxicity assessed independently. The reference case is best used as a reminder to pair translational investigation with careful interpretation of pharmacological and neurological safety signals.